Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Approves MSD’s Oral COVID-19 Drug Molnupiravir
The Japanese government granted special emergency approval for MSD’s antiviral Lagevrio Capsules (molnupiravir) on December 24, making it the country’s first oral treatment for COVID-19. Health Minister Shigeyuki Goto approved the drug immediately after it was given the blessing at…
To read the full story
Related Article
- MSD Japan Boosts COVID-19 Pill Supply to 800,000 Courses by March
February 15, 2022
- Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
February 7, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- MSD Japan Set to Supply 1.6 Million Courses of Lagevrio by September: President
January 26, 2022
- MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
December 20, 2021
- MSD Files Oral COVID-19 Drug in Japan
December 3, 2021
- Japan to Receive 1.6 Million Courses of MSD’s COVID-19 Drug
November 11, 2021
REGULATORY
- Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
- Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
March 5, 2026
- MHLW Expands Eligibility for “Specific-Use Drug” Designation
March 5, 2026
- MHLW to Launch Priority Review Pathway for Overseas Alternatives amid Drug Shortages
March 5, 2026
- LDP Health Panel Approves Health Insurance Bill with OTC-Like Drug Charges
March 5, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…